Adderall XR News
Out of the Gate: Shire stock falls - Boston Globe
Prescriptions of Vyvanse are growing slowly, Holford said, meaning Shire will lose customers when the patents on its older drug, Adderall XR, ...
Walking the line - Investors Chronicle
Vyvanse is Shire's replacement for its blockbuster attention deficit and hyperactivity disorder (ADHD) treatment Adderall XR which will run out of patent ...
Shire shares up after net income jumps - Trading Markets (press release)
The maker of top-selling Adderall XR for attention-deficit/hyperactivity disorder also said fourth-quarter revenue rose 46 percent to $724.5 million from ...
Mental models - Atlantic Online
There is a link for people who are already taking Adderall. "Congratulations!" it reads. "By taking ADDERALL XR, you're showing your commitment to reaching ...
Shire shares up after net income jumps - Philadelphia Inquirer
The maker of top-selling Adderall XR for attention-deficit/hyperactivity disorder also said fourth-quarter revenue rose 46 percent to $724.5 million from ...
Shire pharmaceuticals healthy after ADHD drug fears - Telegraph.co.uk
Adderall XR is Shire's best-selling drug with revenue of $1bn in 2007. Sales are expected to plummet when it goes off patent early next year. ...
Shire Profit Triples on Sales of Vyvanse ADHD Drug (Update3) - Bloomberg
The company needs to reduce its reliance on hyperactivity drug Adderall XR, which makes up half of its revenue and loses patent protection next year. ...
UPDATE 1-Shire 2007 earnings top forecast, upbeat on Vyvanse - Reuters
Revenues rose 36 percent to $2.44 billion, boosted by a 19 percent rise in sales of Adderall XR, Shire's current top-selling ADHD treatment, ...
London shares close lower; weakness among miners overshadows bank ... - CNNMoney.com
The broker said that rapid growth of new product sales increases its confidence that the company can offset the loss of ADHD drug Adderall XR sales from May ...
Ahead of the Bell: Shire Shares Rise - Houston Chronicle
Vyvanse is key to Shire's future, as its current top drug, Adderall XR, will lose patent protection next year. Shares of the British drug maker rose $2.85, ...
Adderall XR RSS Feed